The news is directly about Bicycle Therapeutics and is likely to impact its stock. The lowered price target might be seen as a negative signal by some investors, potentially putting downward pressure on the stock. However, the maintained Outperform rating indicates that the analyst still sees the company as a good investment, which could counteract some of the negative impact.